ArticleJapanese journal of radiology2026
Intravoxel incoherent motion diffusion-weighted imaging for early response stratification of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor in renal cell carcinoma: an exploratory study.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeTo evaluate intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) for stratifying early response to neoadjuvant immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) therapy in renal cell carcinoma (RCC) and explore correlations between IVIM‑DWI parameters and tumor immune cell infiltration. MATERIALS AND
methodsThis retrospective exploratory analysis utilized prospectively collected data from a single‑center study enrolling patients with advanced, metastatic or unresectable RCC scheduled for neoadjuvant ICI‑TKI therapy. Two radiologists independently segmented primary tumors on baseline IVIM‑DWI to obtain the true diffusion coefficient (D), pseudo‑diffusion coefficient (D
resultsAmong 58 patients (44 ccRCC), 33 (56.9%) were responders. Responders showed higher baseline D
conclusionIVIM‑DWI parameters show promise as a non‑invasive tool for early response stratification of neoadjuvant ICI‑TKI therapy in RCC. The inverse correlation between D values and CD8⁺ T‑cell infiltration suggests that restricted diffusion may reflect a tumor microenvironment associated with treatment resistance.
Indexed as
Identifiers
42240729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.